Clinical trial
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
NCT05291689 is registered in ClinicalTrials.gov with Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 13, 2022
- Completion date
- February 19, 2025
- Enrollment
- 39 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.